Emerging targets in advanced non-small-cell lung cancer

被引：21

作者：

Valentino, Francesco ^{[1
]}

Borra, Gloria ^{[1
]}

Allione, Paolo ^{[1
]}

Rossi, Lorena ^{[1
]}

机构：

[1] AO Maggiore Carita, Novara, Italy

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 13期

关键词：

new therapeutic candidates; NSCLC; translational clinical trials; OPEN-LABEL; CLINICOPATHOLOGICAL FEATURES; CLINICAL ACTIVITY; KINASE MUTATIONS; BRAF MUTATIONS; HER2; MUTATION; DOUBLE-BLIND; PHASE-II; MET; RET;

D O I：

10.2217/fon-2018-0099

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New therapeutic options in non-small-cell lung cancer have been available through a great in-depth and genomic research, improving preclinical disease patterns and identifying the specific toxicity of target therapy. The multidisciplinary approach, increasingly practiced among clinicians, researchers, pharmaceutical companies and ethics committees has allowed the emergence of a new generation of translational clinical trials and the adoption of new technologies (e.g., point-of-care sequencing), then speeding up the development and trade of these new drugs. Consequently, there is a long list of therapeutic candidates that need to be efficiently evaluated early in the context of Phase I clinical trials. In this review, we discuss some of the key developments and novelties in the main histological groups.

引用

页码：61 / 72

页数：12

共 88 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas [J].

Arcila, Maria E. ;

Chaft, Jamie E. ;

Nafa, Khedoudja ;

Roy-Chowdhuri, Sinchita ;

Lau, Christopher ;

Zaidinski, Michael ;

Paik, Paul K. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2012, 18 (18) :4910-4918

[3] RET tyrosine kinase signaling in development and cancer [J].

Arighi, E ;

Borrello, MG ;

Sariola, H .

CYTOKINE & GROWTH FACTOR REVIEWS, 2005, 16 (4-5) :441-467

[4] Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). [J].

Awad, Mark M. ;

Leonardi, Giulia Costanza ;

Kravets, Sasha ;

Dahlberg, Suzanne Eleanor ;

Drilon, Alexander E. ;

Noonan, Sinead ;

Camidge, D. Ross ;

Ou, Sal-Hong Ignatius ;

Costa, Daniel Botelho ;

Gadgeel, Shirish M. ;

Steuer, Conor Ernst ;

Forde, Patrick M. ;

Zhu, Viola Weijia ;

Fukuda, Yoko Korenaga ;

Clark, Jeffrey W. ;

Janne, Pasi A. ;

Mok, Tony ;

Sholl, Lynette M. ;

Heist, Rebecca Suk .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[5] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[6] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[7] Patient-centric trials for therapeutic development in precision oncology [J].

Biankin, Andrew V. ;

Piantadosi, Steven ;

Hollingsworth, Simon J. .

NATURE, 2015, 526 (7573) :361-370

[8] Mutational analysis of the HER2 gene in lung tumors from Caucasian patients:: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features [J].

Buttitta, Fiamma ;

Barassi, Fabio ;

Fresu, Giuseppina ;

Felicioni, Lara ;

Chella, Antonio ;

Paolizzi, Diego ;

Lattanzio, Giuseppe ;

Salvatore, Simona ;

Camplese, Pier P. ;

Rosini, Sandra ;

Iarussi, Teodorico ;

Mucilli, Felice ;

Mezzetti, Andrea ;

Sacco, Rocco ;

Marchetti, Antonio .

INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (11) :2586-2591

[9] Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) [J].

Camidge, D. Ross ;

Ou, Sai-Hong Ignatius ;

Shapiro, Geoffrey ;

Otterson, Gregory Alan ;

Villaruz, Liza Cosca ;

Villalona-Calero, Miguel Angel ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Dacic, Sanja ;

Cardarella, Stephanie ;

Zhao, Weiqiang ;

Tye, Lesley ;

Stephenson, Patricia ;

Wilner, Keith D. ;

James, Leonard Philip ;

Socinski, Mark A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[10] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

← 1 2 3 4 5 6 7 8 9 →